MCRBSeres Therapeutics, Inc.

Nasdaq serestherapeutics.com


$ 1.01 $ 0.08 (7.98 %)    

Monday, 09-Sep-2024 15:59:54 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.03
$ 0.97
$ 1.01 x 3,326
$ 1.02 x 300
$ 0.92 - $ 1.11
$ 0.54 - $ 3.24
5,787,186
na
156.28M
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-07-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 03-02-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 07-28-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-seres-therapeutics-maintains-10-price-target

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.

 chardan-capital-maintains-buy-on-seres-therapeutics-maintains-125-price-target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.

 seres-therapeutics-has-signed-an-agreement-with-socit-des-produits-nestl-for-the-sale-of-its-vowst-business-to-nestl-health-science-seres-will-receive-capital-infusions-including-an-upfront-payment-a-prepaid-milestone-payment-and-an-equity-investment

In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sale...

 oppenheimer-downgrades-seres-therapeutics-to-perform

Oppenheimer analyst Jeff Jones downgrades Seres Therapeutics (NASDAQ:MCRB) from Outperform to Perform.

 canaccord-genuity-maintains-buy-on-seres-therapeutics-lowers-price-target-to-10

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from...

 seres-therapeutics-entered-into-a-non-binding-memorandum-of-understanding-with-nestl-health-science-for-the-sale-of-seres-vowst-assets-under-the-terms-of-the-pending-agreement-seres-is-due-to-receive-capital-infusions-including-an-upfront-payment

Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend i...

 oppenheimer-maintains-outperform-on-seres-therapeutics-lowers-price-target-to-4

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION